Immunovant (IMVT) Tax Provisions (2018 - 2026)
Immunovant (IMVT) reported Tax Provisions of -$2.9 million for Q1 2026, down 590.39% on a YoY basis from $583000.0 in Q1 2025, and down 284.21% quarter-over-quarter from $1.6 million in Q4 2025.
Immunovant (IMVT) Tax Provisions (2018 - 2026) Analysis & Trends
Immunovant has reported Tax Provisions for 9 years, with the latest figure at -$2.9 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 590.39% year-over-year to -$2.9 million; the trailing twelve-month figure through Mar 2026 stood at $200000.0 (down 77.53% YoY), and the FY2026 full-year result was $200000.0, down 77.55% from the prior year.
- Tax Provisions for Q1 2026 stood at -$2.9 million, down from $1.6 million in the prior quarter.
- The five-year high for Tax Provisions was $1.6 million in Q4 2025, with the low at -$2.9 million in Q1 2026.
- Historically, Tax Provisions has averaged $97294.1 across 5 years, with a median of $232000.0 in 2024.
- Annual changes were most pronounced in 2023 — Tax Provisions tumbled 8158.33% — and 2025, when it soared 1085.71%.
- Immunovant's Tax Provisions stood at $387000.0 in 2022, then tumbled by 127.91% to -$108000.0 in 2023, then soared by 240.74% to $152000.0 in 2024, then jumped by 921.05% to $1.6 million in 2025, then plunged by 284.21% to -$2.9 million in 2026.
- The last three Tax Provisions figures came in at -$2.9 million (Q1 2026), $1.6 million (Q4 2025), and $594000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 216,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.86 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 594,000.00 |
| Jun 30, 2025 | 913,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Dec 31, 2024 | 152,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 232,000.00 |
| Dec 31, 2023 | -108,000.00 |
| Sep 30, 2023 | 454,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | -991,000.00 |
| Dec 31, 2022 | 387,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Mar 31, 2022 | -12,000.00 |
| Sep 30, 2021 | -31,000.00 |
| Jun 30, 2021 | -41,000.00 |
| Mar 31, 2021 | -79,000.00 |